0VGI.L
TG Therapeutics, Inc. [0VGI.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
0VGI.L Stock Summary
Top 0VGI.L Correlated Resources
0VGI.L
Top 10 Correlated ETFs
0VGI.L
Top 10 Correlated Stocks
0VGI.L
In the News
0VGI.L Financial details
0VGI.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0.05 | 0.02 | |
| Net income per share | -2.3 | -1.96 | -2.42 | -2.63 | -1.46 | |
| Operating cash flow per share | -1.71 | -1.5 | -1.86 | -2.24 | -1.3 | |
| Free cash flow per share | -1.71 | -1.5 | -1.86 | -2.24 | -1.3 | |
| Cash per share | 0.91 | 1.59 | 5.25 | 2.38 | 1.19 | |
| Book value per share | 0.32 | 0.44 | 4.5 | 1.79 | 0.43 | |
| Tangible book value per share | 0.58 | 0.43 | 4.5 | 1.79 | 0.43 | |
| Share holders equity per share | 0.32 | 0.44 | 4.5 | 1.79 | 0.43 | |
| Interest debt per share | 0 | 0.33 | 0.07 | 0.51 | 0.53 | |
| Market cap | 910.6M | 1.07B | 1.39B | 1.6B | 1.55B | |
| Enterprise value | 868.64M | 953.64M | 838.2M | 1.3B | 1.44B | |
| P/E ratio | -5.25 | -6.17 | -4.98 | -4.58 | -7.8 | |
| Price to sales ratio | 5.99K | 7.01K | 9.16K | 238.51 | 555.17 | |
| POCF ratio | -7.06 | -8.03 | -6.49 | -5.4 | -8.78 | |
| PFCF ratio | -7.06 | -8.02 | -6.48 | -5.39 | -8.78 | |
| P/B Ratio | 37.88 | 27.61 | 2.68 | 6.73 | 26.39 | |
| PTB ratio | 37.88 | 27.61 | 2.68 | 6.73 | 26.39 | |
| EV to sales | 5.71K | 6.27K | 5.51K | 193.83 | 518.44 | |
| Enterprise value over EBITDA | -4.98 | -5.64 | -3.07 | -3.76 | -7.5 | |
| EV to operating cash flow | -6.74 | -7.18 | -3.91 | -4.39 | -8.2 | |
| EV to free cash flow | -6.73 | -7.17 | -3.9 | -4.38 | -8.2 | |
| Earnings yield | -0.19 | -0.16 | -0.2 | -0.22 | -0.13 | |
| Free cash flow yield | -0.14 | -0.12 | -0.15 | -0.19 | -0.11 | |
| Debt to equity | 0 | 0.75 | 0.01 | 0.28 | 1.21 | |
| Debt to assets | 0 | 0.18 | 0.01 | 0.18 | 0.37 | |
| Net debt to EBITDA | 0.24 | 0.67 | 2.02 | 0.87 | 0.53 | |
| Current ratio | 2.03 | 1.77 | 6.99 | 5.06 | 3.16 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.74 | 0.77 | 0.77 | 0.85 | 0.89 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 99.74 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 1.05K | 1.01K | 1.09K | 33.28 | 45.01 | |
| Intangibles to total assets | 0.01 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.59 | -0.86 | -2.35 | -0.06 | -0.01 | |
| Capex to depreciation | -1.02 | -1.31 | -2.26 | -1.42 | -0.05 | |
| Stock based compensation to revenue | 111.09 | 75.23 | 528.22 | 9.16 | 6.89 | |
| Graham number | 4.06 | 4.39 | 15.67 | 10.31 | 3.78 | |
| ROIC | -7.26 | -2.5 | -0.52 | -1.13 | -1.49 | |
| Return on tangible assets | -2.09 | -1.07 | -0.45 | -0.92 | -1.03 | |
| Graham Net | 0.4 | 0.18 | 4.33 | 1.31 | 0.2 | |
| Working capital | 40.18M | 64.7M | 524.19M | 265.58M | 115.07M | |
| Tangible asset value | 43.96M | 37.82M | 518.55M | 236.35M | 57.79M | |
| Net current asset value | 40.18M | 24.75M | 505.45M | 188.49M | 33.29M | |
| Invested capital | 0 | 0.75 | 0.01 | 0.28 | 1.21 | |
| Average receivables | 0 | 0 | 0 | 694.5K | 694.5K | |
| Average payables | 31.13M | 33.21M | 33.53M | 43.95M | 40.36M | |
| Average inventory | 0 | 0 | 0 | 0.5 | 0.5 | |
| Days sales outstanding | 0 | 0 | 0 | 75.79 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 23.51K | 41.07K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 4.82 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0.02 | 0.01 | |
| Inventory turnover | 0 | 0 | 0 | 790K | 0 | |
| ROE | -7.22 | -4.48 | -0.54 | -1.47 | -3.39 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.06 | 0.11 | 1.06 | |
| Net income per share | -0.26 | -0.39 | -0.28 | -0.34 | 0.73 | |
| Operating cash flow per share | -0.25 | -0.17 | -0.43 | -0.3 | 0.54 | |
| Free cash flow per share | -0.25 | -0.17 | -0.43 | -0.3 | 0.54 | |
| Cash per share | 1.3 | 1.18 | 1 | 1.03 | 1.47 | |
| Book value per share | 0.74 | 0.43 | 0.2 | 0.29 | 1.06 | |
| Tangible book value per share | 0.74 | 0.42 | 0.19 | 0.28 | 1.05 | |
| Share holders equity per share | 0.74 | 0.43 | 0.2 | 0.29 | 1.06 | |
| Interest debt per share | 0.52 | 0.52 | 0.69 | 0.7 | 0.63 | |
| Market cap | 851.88M | 1.57B | 2.11B | 3.5B | 1.3B | |
| Enterprise value | 742.02M | 1.46B | 2.05B | 3.4B | 1.15B | |
| P/E ratio | -5.95 | -7.39 | -13.43 | -18.38 | 2.86 | |
| Price to sales ratio | 9.06K | 19.57K | 270.14 | 217.79 | 7.86 | |
| POCF ratio | -24.7 | -65.59 | -35.19 | -83.34 | 15.57 | |
| PFCF ratio | -24.69 | -65.58 | -35.19 | -83.34 | 15.57 | |
| P/B Ratio | 8.48 | 26.72 | 76.84 | 86.54 | 7.91 | |
| PTB ratio | 8.48 | 26.72 | 76.84 | 86.54 | 7.91 | |
| EV to sales | 7.89K | 18.29K | 262.26 | 211.75 | 6.95 | |
| Enterprise value over EBITDA | -21.27 | -28.15 | -55.42 | -76.24 | 10.03 | |
| EV to operating cash flow | -21.51 | -61.3 | -34.16 | -81.03 | 13.77 | |
| EV to free cash flow | -21.51 | -61.29 | -34.16 | -81.03 | 13.77 | |
| Earnings yield | -0.04 | -0.03 | -0.02 | -0.01 | 0.09 | |
| Free cash flow yield | -0.04 | -0.02 | -0.03 | -0.01 | 0.06 | |
| Debt to equity | 0.7 | 1.21 | 3.52 | 2.42 | 0.6 | |
| Debt to assets | 0.32 | 0.37 | 0.49 | 0.44 | 0.3 | |
| Net debt to EBITDA | 3.15 | 1.97 | 1.66 | 2.17 | -1.31 | |
| Current ratio | 5.02 | 3.16 | 2.93 | 2.87 | 5.53 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.96 | 0.45 | 1.53 | 0.88 | 0.73 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 221.29 | 370.44 | 2.03 | 1.75 | 0.09 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.04 | -0.04 | 0 | 0 | 0 | |
| Capex to depreciation | -0.05 | -0.04 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 74.35 | 138.14 | 0.87 | 0.78 | 0.06 | |
| Graham number | 2.1 | 1.93 | 1.11 | 1.49 | 4.16 | |
| ROIC | -0.21 | -0.4 | -0.3 | -0.32 | 0.44 | |
| Return on tangible assets | -0.16 | -0.27 | -0.2 | -0.22 | 0.34 | |
| Graham Net | 0.43 | 0.19 | -0.07 | -0.05 | 0.7 | |
| Working capital | 146.48M | 115.07M | 121.71M | 135.91M | 261.44M | |
| Tangible asset value | 99.68M | 57.79M | 26.63M | 39.65M | 163.97M | |
| Net current asset value | 65.51M | 33.29M | 14.86M | 28.17M | 152.82M | |
| Invested capital | 0.7 | 1.21 | 3.52 | 2.42 | 0.6 | |
| Average receivables | 44K | 0 | 4.31M | 13.05M | 28.4M | |
| Average payables | 32.88M | 29.62M | 42.51M | 57.17M | 46.39M | |
| Average inventory | 0.5 | 0 | 13.61M | 28.73M | 31.89M | |
| Days sales outstanding | 0 | 0 | 99.46 | 97.89 | 21.34 | |
| Days payables outstanding | 1.32M | 894.57K | 5.8K | 2.79K | 862.84 | |
| Days of inventory on hand | 0 | 0 | 2.86K | 1.42K | 860.58 | |
| Receivables turnover | 0 | 0 | 0.9 | 0.92 | 4.22 | |
| Payables turnover | 0 | 0 | 0.02 | 0.03 | 0.1 | |
| Inventory turnover | 0 | 0 | 0.03 | 0.06 | 0.1 | |
| ROE | -0.36 | -0.9 | -1.43 | -1.18 | 0.69 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
0VGI.L Frequently Asked Questions
What is TG Therapeutics, Inc. stock symbol ?
TG Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol 0VGI.L
What is TG Therapeutics, Inc. stock quote today ?
TG Therapeutics, Inc. stock price is $15.93 today.
Is TG Therapeutics, Inc. stock public?
Yes, TG Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 13.77K
- Market Capitalization 2.38B
- Employee 245
- CEO Mr. Michael S. Weiss Esq.
- Headquarters New York,NY,US
- IPO Date 2018-11-23
-
Website
https://www.tgtherapeutics.com 
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
